N4 Pharma PLC Operations Update (6273L)
September 14 2021 - 1:00AM
UK Regulatory
TIDMN4P
RNS Number : 6273L
N4 Pharma PLC
14 September 2021
14 September 2021
N4 Pharma plc
("N4 Pharma" or the "Company")
Operations Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to provide a further update on its current
in vivo work streams due to commence shortly with Evotec.
As announced on 24 August 2021, the Company has now successfully
completed the amplification and initial testing of a new SARS-COV-2
plasmid at Evotec and finalised the scope of the in vivo study. The
first step in this new study was to test the in vitro performance
of the new plasmid. The optimised Nuvec(R), together with the new
SARS-COV-2 plasmid has demonstrated an improved response in terms
of transfection and SARS-COV-2 Spike protein secretion in HEK 293
cells, a commonly used human cell line. In addition, the
Nuvec(R)/SARS-COV-2 DNA complex demonstrated a dose-related
SARS-COV-2 Spike protein production. These in vitro results provide
a positive platform for the commencement of the in vivo work
beginning this month which is expected to last six to eight weeks
with an additional two to three weeks for analysis.
Nanomerics's wider in vivo study, as announced on 20 May 2021,
has now validated the results seen from their earlier pilot study,
showing an improvement through the use of newly formulated and
dried Nuvec(R). The findings of this work will now be adopted in
all future work undertaken to ensure all studies are performed
using well dispersed Nuvec(R) formulations.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"The Board is very pleased with these initial in vitro results
from the new SARS-COV-2 plasmid which confirms Nuvec(R) is capable
of producing results in this area and demonstrate a material
improvement on previous results with an earlier plasmid.
"We are very excited to commence the in vivo work using this
SARS-COV-2 plasmid alongside the MTA (Material Transfer Agreement)
work already in place with a potential partner in this area. The
aim of the study is to demonstrate the potential of using Nuvec(R)
to develop plasmid DNA vaccines using much lower doses than those
already approved or are in development and also not requiring
refrigeration."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has
been incorporated into UK law by the European Union (Withdrawal)
Act 2018. Upon the publication of this announcement via Regulatory
Information Service ('RIS'), this inside information is now
considered to be in the public domain.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Tel: +44(0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDLJMRTMTMBBPB
(END) Dow Jones Newswires
September 14, 2021 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Mar 2024 to Apr 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2023 to Apr 2024